Arrhythmias. Cardiac resynchronization therapy in women.
A meta-analysis by investigators from FDA of three major trials of cardiac resynchronization therapy (CRT) demonstrated that women have a reduced rate of heart failure (HF) and death with CRT at a shorter QRS duration than men. Recognizing these sex-specific differences is important to improve outcomes for women with HF.